Random

Progressive Supranuclear Palsy

Neurology Neuroscience Neuroscience Business

·November 4, 2017·7 min read

Cortice Biosciences Announces Presentation of Results from Placebo-Controlled Phase 1 Clinical Trials Evaluating TPI 287 for Treatment of Alzheimer’s Disease and Related Tauopathies

Cortice Biosciences announced today results from placebo-controlled, double-blinded Phase 1 studies evaluating TPI 287, a brain penetrable microtubule stabilizing agent, for the treatment of Alzheimer’s disease, progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).

This image shows a brain on jigsaw pieces.

Featured Neurology

·October 10, 2014·1 min read

Similar But Different: New Discovery for Neurodegenerative Disease

Researchers report people with PSP experience more severe and extensive cognitive impairments than those with Parkinson's disease.

Featured Neurology Neuroscience

·October 13, 2022·5 min read

Memory and Logic Test Detects Dementia Signs up to Nine Years Ahead of Diagnosis

People who later developed Alzheimer's disease scored poorly on memory and logic-based tests, as well as reaction times and grip tests. They were also more likely to have experienced a fall within the past 12 months. Those who developed PSP were twice as likely to experience a fall.

Featured Genetics Neurology Neuroscience Open Neuroscience Articles

·January 5, 2020·5 min read

Up to 10,000 people could be living with rare neurological disorders

Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), two atypical parkinsonian syndromes, may be twice as common as previously believed, researchers report.

Featured Genetics Neurology Neuroscience

·May 19, 2021·6 min read

New Insight Into Protein Production in Brain Could Help Tackle Dementia

Researchers have identified a layer of genetic material involved in controlling the production of tau in the brain. The material is part of a larger family of non-coding genes that regulate and control other brain proteins associated with neurodegenerative disorders, such as Alzheimer's disease, Parkinson's, and PSP. The findings could lead to the development of new therapeutics to treat a range of neurodegenerative disorders.

Featured Neurology Neuroscience Open Neuroscience Articles

·March 19, 2022·5 min read

New Strategy Reduces Brain Damage in PSP, Alzheimer’s, and Related Disorders in Mice

Alpha2-NKA, a protein that drives toxicity in astrocytes, was discovered in higher levels of brain samples from people who died of PSP, Alzheimer's and other tau-related neurodegenerative disorders. Treatment with an FDA-approved drug called digoxin may suppress the inflamed astrocytes and halt disease progression for those with tauopathy disorders.

Featured Genetics Neurology Neuroscience

·August 18, 2022·6 min read

New Dementia Risk Genes Identified Through Novel Testing Approach

Researchers have identified multiple new risk genes for Alzheimer's disease and progressive supranuclear palsy (PSP).

Featured Neurology Neuroscience

·April 4, 2022·7 min read

Loss of Neurons, Not Lack of Sleep, Makes Alzheimer’s Patients Drowsy

Degeneration of neurons associated with wakefulness, and not a lack of sleep, makes Alzheimer's patients more drowsy. The degeneration of these neurons is caused by the tau protein. In PSP, the damage to the neurons was associated with symptoms of sleep deprivation.

Featured Neurology

·September 2, 2015·4 min read

How Tau Accumulates and Caused Neurodegenerative Disorders

A new study reports appoptosin initiates a path that leads to tau accumulation in neurodegenerative disorders.

Featured Neurology Neuroscience

·August 12, 2019·5 min read

Alzheimer’s disease destroys neurons that keep us awake

Tau accumulations disrupt wake-promoting neurons. The findings help explain why day-time napping and sleep disruptions are often reported in Alzheimer's patients.

Featured Neurology Neuroscience

·January 6, 2023·4 min read

Inflammatory Trigger a New Clue in Alzheimer’s and PSP

An inflammatory trigger like one present during viral infections is elevated in those with Alzheimer's disease and progressive supranuclear palsy (PSP).